Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
Medication-induced gastroparesis from Ozempic typically reverses after discontinuation, though symptoms may persist for extended periods in some cases
Ethics declarations Conflict of interest The authors declare no conflicts of interest to disclose
10.1371/journal.ppat.1005449 294 WilcoxD
Statesboro optimal health and wellness specialists at Thrive Family Practice & Med Spa treat obesity, difficulty losing weight, uncontrolled cravings, slow metabolism, and weight-related health concerns using GLP-1 injections in Statesboro and surrounding Bulloch County areas
US$ 26.33
US$ 24.44
US$ 20.31
US$ 20.74
US$ 24.12
US$ 19.98
US$ 25.15
US$ 27.24
